Report: Biopharma’s class of 2013 is laden with blockbusters

Damian Garde

While 's number of approved drugs fell short of 2012's record haul, the is likely to more than make up for that disparity in the dollar column, according to EvaluatePharma.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS